Reaction

Lung Transplant Rejection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 657 reports · 41 co-occurring drugs

As of the last recalculation, Lung Transplant Rejection appears in 657 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is VALGANCICLOVIR (PRR 177.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Valganciclovir	91	177.3	178.2
Valganciclovir Hydrochloride	91	177.3	178.2
Tacrolimus	366	165.9	166.3
Valganciclovir Hydrochloride Powder,	53	149.7	150.3
Basiliximab	39	111.6	112.0
Sirolimus	42	105.4	105.8
Tacrolimus Ointment 0.1%	247	100.1	100.3
Tacrolimus Extended-Release Capsules	247	99.8	100.0
Mycophenolate Mofetil	251	94.1	94.3
Mycophenolate Mofetil Hydrochloride	251	94.0	94.1
Itraconazole	30	85.2	85.4
Ganciclovir Sodium	25	77.8	77.9
Ganciclovir	24	77.1	77.2
Anti-Thymocyte Globulin (Rabbit)	15	60.3	60.4
Everolimus Tablets	30	59.3	59.5
Mycophenilic Acid	31	49.7	49.8
Amphotericin B	17	44.1	44.2
Mycophenolic Acid	40	42.1	42.1
Atovaquone	10	39.9	40.0
Elexacaftor, Tezacaftor, And Ivacaftor	15	39.0	39.0
Azathioprine	93	38.8	38.8
Voriconazole	35	38.5	38.5
Posaconazole Delayed-Release	12	35.2	35.3
Voriconazole Injection	22	33.2	33.2
Cyclosporine	95	31.5	31.5
Micafungin Sodium	8	30.2	30.3
Tenofovir Disoproxil Fumarate Tablets	8	29.7	29.7
Posaconazole	14	27.9	27.9
Amikacin	14	26.5	26.6
Azithromycin	32	26.4	26.4
Daspone	8	26.3	26.4
Dapsone Gel, 5%	8	26.3	26.3
Tobramycin	19	25.7	25.8
Azithromycin Monohydrate	32	25.5	25.6
Tobramycin Solution	9	24.1	24.1
Dapsone	8	24.0	24.0
Tobramycin Sulfate	9	23.3	23.3
Everolimus	33	21.6	21.6
Pancrelipase	23	19.5	19.5
Ivacaftor	3	12.0	12.0
Dornase Alfa	6	9.8	9.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.